Cstone Pharmaceuticals Sustainability Profile
Cstone Pharmaceuticals, also known as Cstone Pharma, is a leading biopharmaceutical company headquartered in China (CN). Founded in 2015, the company has rapidly established itself in the oncology sector, focusing on the development of innovative therapies for cancer treatment. With a strong presence in both domestic and international markets, Cstone operates in key regions including Asia and North America. The company’s core offerings include a range of targeted therapies and immuno-oncology products, distinguished by their unique mechanisms of action and commitment to improving patient outcomes. Cstone Pharmaceuticals has achieved significant milestones, including successful clinical trials and strategic partnerships, positioning itself as a notable player in the global biopharmaceutical landscape. With a dedication to advancing cancer care, Cstone continues to drive innovation and expand its portfolio of life-changing therapies.
DitchCarbon Score
How does Cstone Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Cstone Pharmaceuticals's score of 24 is lower than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Cstone Pharmaceuticals's reported carbon emissions
In 2024, Cstone Pharmaceuticals reported carbon emissions of approximately 379,040 kg CO2e, all of which fall under Scope 2 emissions. This represents a decrease from 2023, where emissions were about 446,630 kg CO2e, also solely from Scope 2. The company has not disclosed any Scope 1 or Scope 3 emissions data. Over the past few years, Cstone Pharmaceuticals has demonstrated a commitment to reducing its carbon footprint. In 2022, the total emissions were about 506,300 kg CO2e, indicating a downward trend in emissions over the years. The GHG emission intensity per employee has also improved, with figures of 3,010 kg CO2e in 2024 compared to 1,950 kg CO2e in 2023. Despite these reductions, Cstone Pharmaceuticals has not set specific reduction targets or initiatives, nor have they committed to any industry-standard climate pledges such as SBTi targets. The company operates independently without cascading emissions data from a parent organization. Overall, Cstone Pharmaceuticals is making strides in managing its carbon emissions, particularly in Scope 2, but further commitments and targets could enhance its climate strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | - | - | - |
| Scope 2 | 591,590 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 |
| Scope 3 | - | - | - | - | - | - |
How Carbon Intensive is Cstone Pharmaceuticals's Industry?
How Carbon Intensive is Cstone Pharmaceuticals's Location?
Cstone Pharmaceuticals's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Cstone Pharmaceuticals has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
